Olanzapine/samidorphan - Alkermes plc

Drug Profile

Olanzapine/samidorphan - Alkermes plc

Alternative Names: ALKS 33/olanzapine; ALKS-3831; Olanzapine/ALKS 33; Samidorphan/olanzapine

Latest Information Update: 21 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alkermes plc
  • Class Amides; Antipsychotics; Benzodiazepines; Cyclopropanes; Morphinans; Oxazepines; Small molecules; Thiazepines
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Opioid mu receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bipolar disorders; Psychotic disorders; Schizophrenia

Most Recent Events

  • 05 May 2018 Additional efficacy and adverse events data from the phase III ENLIGHTEN-1 trial in Schizophrenia presented at the 171st Annual Meeting of the American Psychiatric Association
  • 26 Apr 2018 Alkermes completes enrolment in its phase III ENLIGHTEN-2 trial for Schizophrenia in USA and Puerto Rico (NCT02694328)
  • 29 Mar 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top